ArticleFrontiers in oncology2022

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.

Ting Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.